GlassScriptPhysician profile
Buthayna Alkhatib Dinary
NPI 1902245087
$8,017.41
in general payments reported to CMS, 2019-2025
36 companies · $2,178 in 2025
The $2,178 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $227 · 2021: $610 · 2022: $854 · 2023: $1,610 · 2024: $1,945 · 2025: $2,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,481 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,480.53 |
| Education | $252.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,190.03 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Mallinckrodt Hospital Products INC. | $952.22 | 2020-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $575.64 | 2019-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $519.70 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $447.91 | 2021-2025 | |
| Travere Therapeutics, INC. | $444.77 | 2022-2025 | |
| Glaxosmithkline, LLC. | $404.41 | 2021-2025 | Benlysta |
| Novo Nordisk INC | $383.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $347.88 | 2021-2025 | |
| Janssen Biotech, INC. | $325.45 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Otsuka America Pharmaceutical, INC. | $289.37 | 2019-2025 | Jynarque, Voyxact |
| Aurinia Pharma U.S., INC. | $275.42 | 2021-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $256.63 | 2019-2025 | Rayaldee |
| Ardelyx, INC. | $247.73 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.86 | 2023-2025 | Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $139.66 | 2024 | Exalt Model D |
| Fresenius USA Marketing, INC. | $95.16 | 2022-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $83.41 | 2019-2021 | |
| Baxter Healthcare | $81.97 | 2019 | |
| Mallinckrodt Enterprises LLC | $76.27 | 2019 | |
| Alexion Pharmaceuticals, INC. | $74.02 | 2021-2025 | Strensiq |
| Horizon Therapeutics Plc | $67.97 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $65.88 | 2019-2025 | Veltassa |
| Radius Health, INC. | $65.32 | 2024 | Tymlos |
| Ani Pharmaceuticals, INC. | $63.67 | 2022-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $55.22 | 2023-2025 | Actemra |
| Daiichi Sankyo INC. | $42.53 | 2021-2022 | |
| Lilly USA, LLC | $41.63 | 2025 | Zepbound, Mounjaro |
| Actelion Pharmaceuticals US, INC. | $38.10 | 2023 | Opsumit |
| Scpharmaceuticals INC. | $35.09 | 2025 | |
| Genzyme Corporation | $34.64 | 2019 | |
| Kyowa Kirin, INC. | $20.96 | 2025 | |
| Shire North American Group INC | $17.40 | 2019 | |
| Apellis Pharmaceuticals, INC. | $16.96 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $16.54 | 2022 | |
| Cashflow Solutions, LLC | $13.60 | 2023 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Buthayna Dinary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.